Therapeutics Discovery: Advancing Cancer Treatment
The Therapeutics Discovery division at MD Anderson was created to eliminate the bottlenecks that hamper traditional drug development.
Our team of more than 100 dedicated cancer researchers, doctors, drug developers and scientific experts develops small molecule drugs, biologics and cellular therapies, inspired by the needs of MD Anderson cancer patients and guided by the expertise of the center’s clinicians. To create life-saving transformational medicines quickly, safely and effectively, Therapeutics Discovery works with unparalleled proximity to patients and an unmatched wealth of clinical experience.
Therapeutics Discovery doesn’t bring the “bench to bedside” – it starts with the bench at the bedside – with each patient and their cancer.
The platforms of Therapeutics Discovery are supported by MD Anderson’s Moon Shots Program™.
Our Research Platforms
Therapeutics Discovery is a unique group of clinicians, researchers and drug development experts working collaboratively to develop small molecule, biologic, and cell-based therapies.
Our collaborations with pharmaceutical and biotechnology companies help us bring transformational, life-saving medicines to patients quickly, safely and effectively.
Novel therapeutic antibody advances to AML clinical trials
The Therapeutics Discovery division and leukemia researchers have advanced a first-in-class therapeutic antibody into a Phase I clinical trial for patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms.